We recently demonstrated in all of 4 mouse tumor models, including the ID8 clone of the MOSEC murine ovarian cancer, that repeated delivery to the tumor site of a combination of mAbs to CD137/PD-1/CTLA4 caused long-term tumor regressions and even cures and that a mAb combination which also comprised a mAb to CD19 was even more effective [27]. This evidence concerns the gene CTLA4 and neoplasm.